Nexalin Technology Granted Conditional Nasdaq Listing Extension
Detailed price information for Nexalin Technology Inc (NXL-Q) from The Globe and Mail including charting and trades.
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Nexalin Technology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Nexalin Technology, Inc. is a small-cap company with a market capitalization of $2M. It ranks number 29 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast.
For NXL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -8.0%, measured on 342 forecast dates between 2022-11-11 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 385 forecast dates between 2022-11-11 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NXL included.
Follow NXL free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
| Metric | NXL | Rank |
|---|---|---|
| Market Cap | $2M | 29/30 |
| P/B Ratio | 1.28x | 20/23 |
| EPS | $-0.46 | – |
| Book Value/Share | $1.83 | – |
| Metric | NXL | Rank |
|---|---|---|
| Gross Margin | 81.6% | 5/27 |
| Operating Margin | -3734.9% | 28/28 |
| EBT Margin | -3673.4% | 28/28 |
| Metric | NXL | Rank |
|---|---|---|
| Current Ratio | 1.25x | 24/30 |
| Quick Ratio | 1.10x | 20/29 |
| D/E Ratio | 0.98x | 11/25 |
| Financial Leverage | 1.98x | 11/25 |
| Interest Coverage | 1944.8x | 2/30 |
| Working Capital | $380K | 24/29 |
| Metric | NXL | Rank |
|---|---|---|
| Operating Cash Flow | -$7M | 21/30 |
| Metric | NXL | Rank |
|---|---|---|
| Inventory Turnover | 0.2x | 26/27 |
| Days Inventory | 1668 days | 2/27 |
| Payables Period | 1711 days | 3/24 |
| Metric | NXL | Rank |
|---|---|---|
| Operating Income | -$11M | 21/30 |
| R&D Expense | $2M | 20/28 |
| SG&A Expense | $5M | 23/26 |
| Cost of Goods Sold | $50K | 26/27 |
| Metric | NXL | Rank |
|---|---|---|
| Shares Outstanding | 1M | – |
| Total Current Assets | $2M | 61.9% of assets |
| Cash & Short-term Investments | $1M | 33.3% of assets |
| Accounts Receivable | $50K | 1.7% of assets |
| Inventory | $230K | 7.7% of assets |
| Total Liabilities | $1M | 49.3% of assets |
| Short-term Debt | $1M | 41.6% of assets |
Companies classified under the same SEC industry code as Nexalin Technology, Inc. (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $327M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| VANI Vivani Medical, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $75M |
| OM Outset Medical, Inc. | ▲ | $74M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| VASO Vaso Corp | ▲ | $51M |
| POSC Positron Corp | ▲ | $51M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| POCI Precision Optics Corporation, Inc. | ▲ | $34M |
| ITOC Itonic Holdings Ltd | ▼ | $28M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▶ | $3M |
| NUWE Nuwellis, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▲ | $1M |
| HCIL Hongchang International Co., Ltd | ▼ | N/A |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
Detailed price information for Nexalin Technology Inc (NXL-Q) from The Globe and Mail including charting and trades.
Detailed price information for Nexalin Technology Inc (NXL-Q) from The Globe and Mail including charting and trades.
<?xml encoding="utf-8" ?> Nexalin Technology Inc. NXL stock surged Thursday after the micro-cap medical technology company signed a 10-year distribution and manufacturing agreement covering seven ...
Our AI ranks Nexalin Technology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For NXL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -8.0%, measured on 342 forecast dates between 2022-11-11 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 385 forecast dates between 2022-11-11 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Nexalin Technology, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
32 issuers in our coverage, NXL included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.